← Back to Search

Monoclonal Antibodies

lerodalcibep for High Cholesterol (LIBerate-H2H Trial)

Phase 3
Waitlist Available
Research Sponsored by LIB Therapeutics LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights

LIBerate-H2H Trial Summary

This trial found that LDL-C reductions at Week 12 were similar for LIB003 300 mg SC administered Q4W and evolocumab 420 mg and alirocumab 300 mg administered Q4W.

Eligible Conditions
  • High Cholesterol
  • Cardiovascular Disease

LIBerate-H2H Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
LDL-C reduction from baseline at 12 weeks
Secondary outcome measures
Achieved ESC/EAS LDL-C goals
tolerability and safety of each treatment: injection site reactions

LIBerate-H2H Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: LIB003 (lerodalcibep)Experimental Treatment1 Intervention
300 mg SC Q4W
Group II: evolocumabActive Control1 Intervention
420 mg SC Q4W
Group III: alirocumabActive Control1 Intervention
300 mg SC Q4W
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
lerodalcibep
2022
Completed Phase 3
~770

Find a Location

Who is running the clinical trial?

LIB Therapeutics LLCLead Sponsor
10 Previous Clinical Trials
4,701 Total Patients Enrolled
Evan A Stein, MD PhDStudy DirectorLIB Therapeutics
5 Previous Clinical Trials
2,057 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients
2021. "Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04790513.
~51 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top